LY-2382770
As of the edition of 20 October 2026, LY-2382770 is a drug: stopped in 2014; acts on TGFB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2014
- Kind
- Unknown
- Registered trials
- 1, 1 stopped early
- Disease areas
- Hormones; Immune system; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of LY-2382770.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TGFB1 | Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide | P01137 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2010 to now |